Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15241302 | 0.88 | PARP10 (0.46) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL25295924 | 0.81 | KMT2A (0.49) | LMNAL3MBTL1TDP1NPC1RAB9A | |
| SCHEMBL11035695 | 0.77 | CYP19A1 (0.47) | LMNAF2TSHRL3MBTL1TDP1 | |
| SCHEMBL27715329 | 0.77 | ELANE (0.56) | LMNATSHRL3MBTL1HTTNPC1 | |
| SCHEMBL128494 | 0.77 | — | — | |
| SCHEMBL6966111 | 0.76 | LMNA (0.42) | LMNAF2TSHRL3MBTL1TDP1 | |
| SCHEMBL16797417 | 0.76 | LMNA (0.50) | LMNAF2TSHRL3MBTL1TDP1 | |
| SCHEMBL411055 | 0.75 | CYP1A2 (0.50) | TSHRL3MBTL1TDP1HTTNPC1 | |
| SCHEMBL27693159 | 0.75 | MAPK1 (0.46) | TSHRL3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL27765588 | 0.74 | ELANE (0.40) | LMNATSHRL3MBTL1TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117042759-A | IL-31 production inhibitor and pharmaceutical composition containing the same | 国立大学法人九州大学 | 2023-11-10 | — | — | CN | disclosed |
| EP-4214198-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
| CN-113329789-A | Pyrazoles as hemoglobin modulators | 辉瑞公司 | 2021-08-31 | — | — | CN | disclosed |
| WO-2020123855-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3377473-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| CN-102781942-B | Octahydro pyrrolo-[3,4-c] pyrroles is replaced as two of orexin receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-09-23 | — | — | CN | disclosed |
| CN-102369196-B | Azetidines as histamine h3 receptor antagonists | EVOTEC NEUROSCIENCES GMBH | 2015-05-20 | — | — | CN | disclosed |
| CN-104411707-A | Substituted phenylimidazopyrazoles and their use | Bayer Pharma AG | 2015-03-11 | — | — | CN | disclosed |
| CN-101405277-A | Dicarbonylic compounds with antibacterial activity | SALVAT LAB SA (ES) | 2009-04-08 | — | — | CN | disclosed |
| EP-1924563-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| CN-1976932-A | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2007-06-06 | — | — | CN | disclosed |
| CN-1938309-A | Crf receptor antagonists and methods relating thereto | SB PHARMCO INC (PR) | 2007-03-28 | — | — | CN | disclosed |
| WO-2007025892-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| CN-1197849-C | 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors | AMERICAN CYANAMID CO (US) | 2005-04-20 | — | — | CN | disclosed |
| CN-1466572-A | Pyrrole derivatives | ס����ҩ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| CN-1337952-A | 2,3,4, 5-tetrahydro-1H- [1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors | AMERICAN CYANAMID CO (US) | 2002-02-27 | — | — | CN | disclosed |
| CN-1293663-A | 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamix acids as matrix metal-protease | AMERICAN CYANAMID CO (US) | 2001-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD17B1, HSD17B2, HSD3B2 | LMNA 3237/4885F2 3175/4885TSHR 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.